(GOVXW) –
-
GeoVax to Present at the 2024 BIO CEO & Investor Conference
-
Geovax (GOVX) Secures Multi-Product License for ProBioGen's AGE1.CR.pIX Suspension Cell Line
-
GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development
-
GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference
-
GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023
-
Geovax Labs (GOVX) Announces Issuance of Ebola Vaccine Patent
-
GeoVax Announces Issuance of Ebola Vaccine Patent
-
Geovax Labs (GOVX) Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
-
GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
-
GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference
-
GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference
-
Geovax Labs Inc. (GOVX) Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights
-
GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights
-
Geovax Labs Inc. (GOVX) Partners With ABL to Advance cGMP Production of Vaccine Candidates
-
GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates
-
GeoVax to Participate in Upcoming Industry Meetings
-
Geovax Labs's (GOVX) Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients
-
GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients
-
GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings
-
GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference
-
GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update
-
GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host
-
GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023
-
Geovax Labs Inc. (GOVX) Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses
-
GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses
-
GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate
-
Geovax Labs (GOVX) Presents Data for GEO-MM01
-
GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress
-
GeoVax to Participate at the World Vaccine Congress with Multiple Presentations
-
GeoVax Reports 2022 Year-End Financial Results and Provides Corporate Update
-
GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress
-
GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update
-
GeoVax to Participate at the 35th Annual Roth Conference
-
GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections
-
Geovax (GOVX) and EmVenio Collaborate to Expand Phase 2 COVID-19 Booster Vaccine Trial
-
GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial
-
GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines
-
Geovax Labs Inc. (GOVX) Expands Gedeptin Clinical Research for Advanced Head and Neck Cancers
-
GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers
-
GeoVax to Present at the 2023 BIO CEO & Investor Conference
-
Geovax Labs (GOVX) Receives Notice of Allowance for Zika Vaccine Patent
-
GeoVax Receives Notice of Allowance for Zika Vaccine Patent
-
GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023
-
Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax
-
Geovax Labs Inc. (GOVX) Appoints Jayne Morgan, M.D., to its Board of Directors
-
GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors
-
GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022
-
GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update
-
GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022
-
GeoVax to Present at Vaccines Summit-2022
Back to GOVXW Stock Lookup
